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Abstract: Background Levodopa (L-DOPA) provided to patients with Parkinson’s disease causes an
increase in dopamine and methoxytyramine blood concentration which may lead to erroneous diagnosis of
dopamine-producing tumours based on a plasma fractionated metanephrines and methoxytyramine assay.
Considering that oral L-DOPA is mainly transformed in the gut wall into dopamine and methoxytyramine,
we hypothesize that patients treated with L-DOPA produce predominantly sulphated methoxytyramine,
whereas dopamine-producing tumours, devoid of sulfotransferase, will secrete free methoxytyramine.
These metabolic differences may allow for discrimination between the two groups of patients through
methoxytyramine plasma concentration. Methods We retrospectively investigated a cohort of 16 patients
with a dopamine-secreting pheochromocytoma or paraganglioma and 22 patients treated for Parkinson’s
disease to see whether the metabolic ratio of free and sulphated methoxytyramine differs. Results Receiver
operating characteristic curve analysis indicates an absolute separation between the two groups when
using a cut-off of free/total methoxytyramine (sum of free and sulphated methoxytyramine) ratio of
0.0059, corresponding to a free methoxytyramine fraction of 0.59% (P < 0.0001, AUC 1.0 indicating
100% sensitivity and specificity). Conclusion Dopamine secreted by tumours and exogenous dopamine
(from Parkinson’s disease treatment) follow different metabolic pathways. We observed that free/total
methoxytyramine ratio may be a useful tool in distinguishing between patients with a dopamine-secreting
tumour from patients treated with L-DOPA when clinical information is incomplete or lacking.
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Abstract
Background: Levodopa (L-DOPA) provided to patients with Parkinson’s disease causes an increase in dopamine and
methoxytyramine blood concentration which may lead to erroneous diagnosis of dopamine-producing tumours based
on a plasma fractionated metanephrines and methoxytyramine assay. Considering that oral L-DOPA is mainly trans-
formed in the gut wall into dopamine and methoxytyramine, we hypothesize that patients treated with L-DOPA produce
predominantly sulphated methoxytyramine, whereas dopamine-producing tumours, devoid of sulfotransferase, will
secrete free methoxytyramine. These metabolic differences may allow for discrimination between the two groups of
patients through methoxytyramine plasma concentration.
Methods: We retrospectively investigated a cohort of 16 patients with a dopamine-secreting pheochromocytoma or
paraganglioma and 22 patients treated for Parkinson’s disease to see whether the metabolic ratio of free and sulphated
methoxytyramine differs.
Results: Receiver operating characteristic curve analysis indicates an absolute separation between the two groups when
using a cut-off of free/total methoxytyramine (sum of free and sulphated methoxytyramine) ratio of 0.0059, correspond-
ing to a free methoxytyramine fraction of 0.59% (P< 0.0001, AUC 1.0 indicating 100% sensitivity and specificity).
Conclusion: Dopamine secreted by tumours and exogenous dopamine (from Parkinson’s disease treatment) follow
different metabolic pathways. We observed that free/total methoxytyramine ratio may be a useful tool in distinguishing
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Dopamine (DA) undergoes a complex metabolism that
has been thoroughly studied over the last decades.
However, differences in the fate of dopamine when it
derives from endogenous pathologic secretion or when
it is orally administrated in the form of levodopa
(L-DOPA), are worth being investigated. While medi-
cation and diet are the main sources for exogenous
L-DOPA, endogenous L-DOPA derives from tyrosine
hydroxylation by tyrosine hydroxylase (TH, EC
1.14.16.2), the rate limiting enzyme for catecholamine
(CAT) production in the cytoplasm of CAT-producing
cells (e.g. nerve endings and chromaffin cells from the
adrenal medulla). L-DOPA is known to increase the
concentration of circulating DA and methoxytyramine
(MT). L-DOPA treatment in Parkinson’s disease (PD)
patients is a frequent preanalytical pitfall when diagnos-
ing DA-secreting pheochromocytoma (PHEO) or para-
ganglioma (PGL) bymeasurement of plasma-fractioned
metanephrines (MNs) and MT concentrations.1
Several reports have highlighted the importance of a
detailed drug history in order to prevent misdiagnosis
of PHEO/PGL, especially for patients on PD medica-
tion.2–4 However, when the information on patient’s
medication is limited, it can preclude the interpretation
of high MT results.
A recent study has brought new insights to discrim-
inate patients on L-DOPA therapy from the patients
affected by a PHEO/PGL that produce normetanephr-
ine (NMN) and metanephrine (MN) based on plasma
and/or urine MNs tests.5 However, as highlighted by
the authors, this study did not include tumours
exclusively secreting DA. These tumours are rare and
difficult to diagnose because affected individuals are
often asymptomatic or suffer from unspecific symp-
toms such as nausea, weight loss, or hypotension, but
not hypertension.6–8
Considering the current knowledge of L-DOPA
metabolism, our hypothesis is that the free/total MT
ratio in plasma may differ in patients treated with
L-DOPA co-prescribed with aromatic-amino acid-
decarboxylase (AADC) and/or catechol-O-
methyltransferase (COMT) inhibitors as compared with
patients affected by PHEO/PGL which exclusively
secrets DA and MT.
Materials and methods
We performed a retrospective, anonymized, systematic
search of our lab results since 2008 for patients
suspected of having PHEO/PGL, exhibiting isolated
elevations in MT: high plasma concentrations of MT
(free MT> 0.06 nmol/L and total MT> 4.19 nmol/L)
and NMN and MN concentrations below our upper
reference limit.9 This search identified 208 records
corresponding to 146 patients fulfilling the selection
criteria. Among these, clinical information was avail-
able for 38 subjects, allowing for their inclusion in our
investigation. Twenty-two (12 females) were PD
patients treated with L-DOPA and 16 patients (7
females) were diagnosed with a DA-only secreting
tumour based on biochemical tests (MNs, MT and
CAT quantification) and confirmed by imaging techni-
ques, or by histology in case of tumour resection. For
all patients included in the L-DOPA group, no PGL or
PHEO were diagnosed for at least several months after
the biochemical measurements. Data from these two
patient groups were further compared with the results
of 75 control subjects (no PHEO/PGL or L-DOPA
treatment) known for hyperaldosteronism and treated
for hypertension recruited for another study (unpub-
lished results). Free and total MT values are expressed
in nanomoles of metabolite per litre of plasma.
All blood samples were collected using a forearm
venous cannula, with the patient kept supine for at
least 15 min before sampling. Patients were instructed
to fast and to abstain from caffeinated and alcohol
beverages and tobacco for 24 h before blood collection.
All samples were collected onto ice and centrifuged
within 30 min after puncture. Plasma was kept at
80 C until analysis. Total MNs and MT were
desulphated using perchloric acid method or treated
with sulphatase as described in a previous study.10
Total and free MNs and MT were extracted on
mElution plate and quantified by ultraperformance
liquid chromatography-tandem mass spectrometry
(UPLC-MS/MS).11,12 The validation of the method to
quantify free MNs and MT was described by Peaston
and colleagues and calculated CV inter-assay from
three different concentrations and 20 different assays
was reported to be lower than 13% for MT.12 In no
case would the inter-assay imprecision interfere with
the high significance of the free/total MT ratio. The
method used for free and total MT quantification is
identical after the deconjugation treatment applied to
the sulphated MNs and MT.10




software was used for all further sta-
tistical calculations (version 14.0 StataCorp, College
Station, TX, USA). Graphs were prepared using the
Prism software (Version 7.03, GraphPad Software,
La Jolla, CA, USA).
This investigation was conducted according to the
Swiss law for clinical research, the international good
clinical practice (GCP) and ICH requirements. The
regional ethics committee for the Canton de Vaud
reviewed and approved this study.
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Results
Thirty-eight subjects were included in our investiga-
tion: 22 in the L-DOPA treatment group and 16 in
the DA-tumour group. Patients in the L-DOPA
group are older than those in the DA-secreting
tumour group: geometric means (CI 95%) are 75.1
(71.7–78.7) and 47.9 years (39.4–58.2), respectively
(P< 0.001) (Table 1 and Supplemental Table 1).
Their renal function, as reported by their physician
and evaluated by the glomerular filtration rate (GFR,
ml/min), is lower in L-DOPA-treated patients than in
the DA-tumour group: geometric means (CI 95%) are
67.9 (58.5–78.7) and 88.5 ml/min (76.0–103.1), respec-
tively (P¼ 0.006).
While we find comparable freeMT plasma concentra-
tions between both patient groups (P¼ 0.16, Wilcoxon
rank-sum test): geometric means (95% CI) 0.28 (0.19–
0.41) and 0.47 nmol/L (0.24–0.94) (Table 1, Figure 1
(a)), we observe a higher total MT concentration in the
L-DOPA-treated group compared with the DA-secreting
tumour group (P< 0.001): geometric means (95% CI)
194 (140.1–268.5) and 26.2 nmol/L (15.4–44.4), respec-
tively (Table 1, Supplemental Table 1, Figure 1(b)).
The free/total MT ratio is lower in the L-DOPA-
treated group compared with the DA-secreting
tumour group (P< 0.001): geometric means (95%
CI) 0.0014 (0.0010–0.0020) and 0.0180 (0.0129–
0.0252), respectively (Table 1, Supplemental Table 1,
Figure 1(c)). Using simple linear regression analysis,
we find that GFR has no significant influence on free
MT concentration; however, it may have an impact
on total MT concentration (P¼ 0.004, adjusted R2:
0.20). When GFR was tested together with age in a
multiple linear regression, only age has a significant
impact on total MT with a modest impact on the
interpretation of the data. When focusing on the
free/total MT ratio, a superimposable impact of
GFR and age was found with the following associated
regression coefficient (e.g. adjusted R2: 0.35 for the
influence of GFR and 0.41 for the influence of age
on MT ratio; P< 0.001) (Figure 2).
Receiver operating characteristic (ROC) curve anal-
yses (Figure 3) are used to discriminate between
patients treated with L-DOPA from those having a
DA-secreting tumour. ROC curves indicate no signifi-






















































Figure 1. Plasma concentration of free MT (a), total MT (b) and ratio free/total MT (c) for control patients, levodopa-treated
patients and patients affected by a DA-only secreting tumours.
MT: methoxytyramine.
Table 1. Free MT, total MT and free/total MT concentration in plasma in nmol/L, age (years) and GFR values (ml/min) for the
three groups.
Free MT Total MT Free/total MT Age GFR
(nmol/L) (nmol/L) (nmol/L) (years) (ml/min)
Levodopa, n¼22
Geo. mean 0.28 194 0.0014 75.1 67.9
Range 0.08–1.53 41.7–580 0.00027–0.0057 61–89 37–103
Pheo/PGL, n¼16
Geo. mean 0.47 26.2 0.018 47.9 88.5
Range 0.07–2.78 5.17–112.8 0.006–0.103 25–80 39–142
Control, n¼75
Geo. mean 0.01 4.5 0.0028 48.2 85.4
Range 0.01–0.03 2.55–9.95 0.001–0.01 24–71 35–145
PGL: paraganglioma; MT: methoxytyramine; GFR: glomerular filtration rate.
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AUC 0.63, 95% CI 0.44–0.83). For total MT, we are
able to significantly distinguish between both groups
(P< 0.0001, AUC 0.94, 95% CI 0.88–1.01), and find
an absolute separation between the two groups with a
cut-off free/total MT ratio of 0.0059, corresponding to
a free MT fraction of 0.59% (P< 0.0001, AUC 1.0
meaning 100% sensitivity and specificity).
Discussion
L-DOPA is a prodrug. After oral administration, its
bioavailability is approximatively 70–100% when co-
prescribed with carbidopa or benserazide. These two
inhibitors prevent the peripheral transformation of
L-DOPA into DA, enabling a larger proportion of
L-DOPA to cross the blood–brain barrier.13 Its absorp-
tion occurs in the duodenum and proximal jejunum.14
L-DOPA then undergoes a complex metabolism. It is
transformed by the action of AADC (EC 4.1.1.28) into
DA, which is further metabolized into MT within cells
containing the enzyme COMT (EC 2.1.1.6).
Sulfotransferase 1A3 (SULT1A3, EC 2.8.2) is the
main enzyme involved in L-DOPA, DA and MT sul-
phation.15 Only a small fraction of L-DOPA in plasma
is detected in its sulphated form, while a large propor-
tion of DA (>90%) and MT circulate in their sulph-
ated form.16 According to the literature, DA sulphate
production takes place mainly in the gastrointestinal
tract16,17; therefore, mesenteric organs receiving exoge-
nous Tyrosine, L-DOPA, and DA harbour strong
expression of SULT1A3 and are considered as the
major production site of DA- and MT-sulphate conju-
gates.17 This contrasts with DA-secreting tumours
devoid of SULT1A3 which exclusively produce free
DA from tyrosine, and subsequently MT through the
action of local COMT.15
Our data found significantly higher total MT con-
centrations in the L-DOPA group compared with the
DA-secreting tumour group, whereas comparable free
MT plasma concentrations were observed in both
groups. We observed that L-DOPA, depending on its
origin (medication or tumoural), follows different met-
abolic pathways. After oral administration, L-DOPA is
transformed into sulphated DA and MT, causing a
massive amount of sulphated MT to enter the portal
circulation, decreasing the free/total ratio of MT in
L-DOPA-treated patients compared with the DA-
secreting tumour group. Nutriments rich in tyrosine,
the precursor of DA, may also give rise to an increase
of both free and sulphated MT, which could ultimately
influence our results.18 However, in our study, the free
and total MT values above our upper reference limits
were due to either a tumour or to levodopa medication.
Excess total MT concentration is found in plasma of
patients taking L-DOPA, causing a lower free/total
MT ratio which enables discrimination between
patients from both groups, as supported by a ROC
curve analysis. According to our ROC curve analyses,
no significant discriminating potential was identified
for free MT, while total MT allowed for distinguishing
both groups. However, an absolute separation of both
groups (100% sensitivity and specificity) was observed
with the free/total MT ratio with a cut-off correspond-
ing to a free MT fraction of 0.59%.
Alterations in the metabolic reaction sequence in the
L-DOPA pathway may also account for some of the
observed differences in MT ratio between both groups.
Enzymatic inhibitions (AADC and COMT) may pro-
vide more L-DOPA available to SULT1A3, possibly
resulting in an increased conversion of both exogenous
and endogenous free L-DOPA to sulphated L-DOPA
in peripheral tissue. AADC and COMT inhibition may




















Figure 2. Free/total MT ratio according to age in the L-DOPA




















Figure 3. ROC curves for free MT, total MTand ratio free/total
MT to discriminate between L-DOPA medication and
DA-secreting tumours.
MT: methoxytyramine.
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be incomplete, allowing transformation into DA and
MT. Moreover, a recent study reported that DA
was able to induce SULT1A3 expression.19
The administration of large amounts of L-DOPA
may therefore increase the production of sulphated
DA and MT. In favour of this hypothesis, the free/
total MT ratio shows an increased sulphation of MT
in the L-DOPA group compared with the DA tumour
group (0.1% vs. 1.8% of free forms, P< 0.001).
However, this hypothesis must be cautiously consid-
ered due to a large variability in L-DOPA inter-
patient regimen (e.g. dosage and duration).
The observed age difference between our two groups
is inherent to the nature of the studied diseases, and in
addition, older subjects are more prone to have a lower
GFR. A statistically significant but modest influence of
GFR was observed on total MT concentrations and on
the free/total MT ratio. However, this impact should
be balanced, as it may only reflect the confounding
influence of age on both total MT concentrations
and GFR. Indeed, testing together age and GFR
revealed a significant (but clinically modest) impact
only for age.
A limitation of this study relies on factors not con-
sidered in our analysis that may also account for the
large variability of free and total plasma MT concen-
tration such as L-DOPA administration route, the
amounts of drug or the presence of AADC and/or
COMT inhibitors. Although pharmacokinetic consid-
erations have not been accounted for in this study, we
are able to consistently observe the high discriminating
potential of the free/total MT ratio.
Conclusion
In this study, we aim to decipher how L-DOPA metab-
olism, specifically its transformation into DA and MT
and their sulphation by SULT1A3, may differ depend-
ing on the metabolic path and production site. Oral
administration of high amounts of L-DOPA, which
undergoes hepatic first path transformation, associated
to AADC and/or COMT inhibitors lead to a metabo-
lite ratio which differs from DA produced and secreted
by tumour cells. We indeed observed that quantifica-
tion of free and total MT in plasma and calculating the
free MT fraction allows differentiation between
patients taking L-DOPA from patients affected by a
DA-only secreting tumour.
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